ID   ADK-VR2 AG143
AC   CVCL_E6J6
RX   PubMed=36519016;
CC   Population: Southeast Asian; Filipino.
CC   Characteristics: Grown in 3D culture in the presence of crizotinib. Has a significantly lower sensitivity to crizotinib than the parental cell line in adherent cultures and is not sensitive to lorlatinib, entrectinib and DS-6051b (PubMed=36519016).
CC   Doubling time: 25.77 hours (Direct_author_submission).
CC   Selected for resistance to: ChEBI; CHEBI_64310; Crizotinib (Xalkori).
CC   Sequence variation: Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:10661; SDC4; Name(s)=SDC4-ROS1; Note=SDC4 exon 2 fused to ROS exon 32 (PubMed=36519016).
CC   Donor information: Established from a treatment-naive non-smoker patient (PubMed=36519016).
CC   Miscellaneous: Doubling time and ethnic origin of patient from personal communication of Angelicola, Stefania.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_E6J5 ! ADK-VR2
SX   Male
AG   46Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=36519016; DOI=10.21037/tlcr-22-163; PMCID=PMC9742620;
RA   Ruzzi F., Angelicola S., Landuzzi L., Nironi E., Semprini M.S.,
RA   Scalambra L., Altimari A., Gruppioni E., Fiorentino M., Giunchi F.,
RA   Ferracin M., Astolfi A., Indio V., Ardizzoni A., Gelsomino F., Nanni P.,
RA   Lollini P.-L., Palladini A.;
RT   "ADK-VR2, a cell line derived from a treatment-naive patient with
RT   SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a
RT   novel preclinical model for new drug development of ROS1-rearranged
RT   NSCLC.";
RL   Transl. Lung Cancer Res. 11:2216-2229(2022).
//